Physician profile
Stephen C Thompson
NPI 1447354956
$4,828.73
in general payments reported to CMS, 2019-2025
31 companies · $632 in 2025
The $632 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $546 · 2020: $371 · 2021: $612 · 2022: $955 · 2023: $1,027 · 2024: $686 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $839.26 | 2019-2025 | Airsupra, Farxiga, Bevespi Aerosphere |
| Novo Nordisk INC | $689.38 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $470.42 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $375.50 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $358.92 | 2021-2024 | Vraylar, Ubrelvy, Qulipta |
| Janssen Pharmaceuticals, INC | $289.35 | 2019-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $256.40 | 2019-2025 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $249.74 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $244.11 | 2021-2024 | Eliquis, Camzyos |
| Pfizer INC. | $192.05 | 2019-2025 | |
| Amarin Pharma, INC. | $158.38 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $101.29 | 2024-2025 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.44 | 2022-2025 | Xifaxan |
| Dexcom, INC. | $55.88 | 2021-2024 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $51.14 | 2022-2023 | Gvoke Hypopen |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $50.06 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $43.09 | 2021-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $41.82 | 2021 | |
| Abbott Laboratories | $34.98 | 2024 | Freestyle Libre 3 |
| Mylan Specialty L.P. | $32.71 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $31.16 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $28.40 | 2019 | |
| Astellas Pharma US INC | $27.75 | 2025 | Veozah |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.40 | 2024 | Lifevest |
| Allergan, INC. | $21.08 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $16.43 | 2025 | |
| Lundbeck LLC | $16.19 | 2025 | Vyepti |
| Corcept Therapeutics | $14.65 | 2020 | |
| Supernus Pharmaceuticals, INC. | $14.25 | 2021 | |
| Philips North America LLC | $13.95 | 2019 | |
| Heartflow, INC. | $13.55 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.